Dengue Fever: Complete Clinical Overview

What it is

Clinical picture

• Incubation: 4-10 days
• Classic dengue fever ("breakbone fever"): high fever, severe headache, retro-orbital pain, myalgia/arthralgia, macular/maculopapular rash, leukopenia, thrombocytopenia (Washington Manual of Medical Therapeutics; ROSEN's Emergency Medicine, p. 2630)
• Minor bleeding signs: petechiae, purpura, ecchymosis, epistaxis, gum bleeding, positive tourniquet test

Warning signs (watch for these - signal progression to severe dengue)

• Severe/persistent abdominal pain
• Persistent vomiting
• Bleeding from mucosa (gums, nose, GI)
• Lethargy, restlessness, or altered mental status
• Liver enlargement (>2 cm)
• Rising hematocrit with falling platelets (hemoconcentration)
• Clinical fluid accumulation (pleural effusion, ascites)
• Postural hypotension

Severe dengue / "problems" (complications)

1. Dengue hemorrhagic fever (DHF): plasma leakage (rising hematocrit, effusions/ascites) + thrombocytopenia + fever 2-7 days + hemorrhagic tendency
2. Dengue shock syndrome (DSS): DHF plus circulatory collapse - the most severe, life-threatening form
3. Hepatic: hepatitis, occasionally fulminant liver failure
4. Renal: acute kidney injury (via hypoperfusion, rhabdomyolysis, hemolysis in G6PD deficiency, acute tubular necrosis, and rarely immune-complex glomerulonephritis or anti-GBM disease), proteinuria (sometimes nephrotic-range), hemolytic uremic syndrome, electrolyte disturbances (Comprehensive Clinical Nephrology, p. 978-979; Brenner & Rector's The Kidney)
5. Respiratory: diffuse alveolar damage/ARDS-type picture from severe leakage
6. Neurological: encephalopathy, reduced consciousness
7. Pregnancy: risk of vertical transmission around delivery, and maternal infection is linked to preterm birth, low birth weight, and fetal distress (Creasy & Resnik's Maternal-Fetal Medicine; Mayo Clinic)
8. Antibody-dependent enhancement: second infection with a different serotype (especially DENV-2) is the classic setup for severe disease - non-neutralizing antibodies from the first infection actually help the second virus enter macrophages via Fc receptors

Drugs and treatment - what actually works and what to avoid

• Acetaminophen (paracetamol) for fever/pain
• Oral or IV fluid/electrolyte replacement (oral rehydration solutions reverse early shock)
• Tepid sponging for fever control
• Close monitoring of hematocrit, platelets, and hemodynamics
• Blood/platelet products only if significant bleeding or per clinical protocol (not prophylactically for isolated thrombocytopenia)
• ICU-level support (IV fluids, organ support) for DHF/DSS

• Aspirin and other NSAIDs (e.g., ibuprofen) - these worsen bleeding tendency and are explicitly warned against by WHO, CDC, and every clinical source reviewed
• Unnecessary IM injections (bleeding risk)
• Steroids - evidence for steroid use in severe dengue remains inconclusive/low-quality; not currently recommended

Prevention

1. Vector control - the primary strategy: eliminate standing water/breeding sites, use screens, air conditioning, EPA-approved insect repellents, protective clothing, and daytime bite avoidance (Aedes bites mainly during the day). Even highly resourced places like Singapore still struggle to fully control outbreaks because mosquitoes breed in tiny water pockets.
2. Novel vector approaches - intentional release of Wolbachia-infected Aedes mosquitoes (which suppress viral replication/transmission) has reduced dengue cases by 95-97% in trial areas of Colombia - a promising expanding strategy.
3. Vaccines:
   • Dengvaxia (CYD-TDV) and the newer tetravalent Qdenga (TAK-003) are available in various countries.
   • Important caution: vaccination in someone without prior dengue infection (seronegative) can theoretically prime for antibody-dependent enhancement and more severe disease on natural infection later - this is why vaccines are generally targeted at people with evidence of prior dengue exposure, particularly in endemic areas.
   • Recent 2025 systematic reviews (PMIDs 41287091, 40195054, 41453168) confirm reasonable efficacy and immunogenicity of tetravalent vaccines, especially in adolescents/prior-exposed individuals, but continue to flag the seronegative-recipient safety signal as something requiring careful pre-vaccination screening or population targeting - worth discussing with a travel medicine/ID specialist before vaccination.

Key cautions to remember

• No second infection is "just like the first" - assume any repeat dengue exposure carries higher severe-disease risk.
• Anyone with dengue and warning signs should be admitted, not managed at home.
• Avoid NSAIDs/aspirin from the moment dengue is suspected, not just confirmed.
• In pregnancy, dengue needs obstetric-infectious disease co-management given fetal risks.
• In endemic-area travelers, distinguish dengue from chikungunya, Zika, malaria, leptospirosis, and other viral hemorrhagic fevers (Ebola, Marburg, yellow fever) since presentations overlap.

Dengue: PubMed Evidence Review (Recent Clinical Trials & Systematic Reviews)

1. Treatment / Drugs - what the trials show

• Doxycycline + Carica papaya leaf extract combination showed the most consistent benefit: shorter hospital stay (7.3 vs 9.1 days) and a larger platelet rise (+154.1 x 10⁹/L vs +66.0 x 10⁹/L over 7 days) than comparators.
• Immunomodulatory drugs overall did not show efficacy, though rupatadine showed some signal for raising platelets.
• Platelet-enhancing agents (recombinant IL-11, anti-D immunoglobulin, eltrombopag) did significantly raise platelet counts, but these are not standard-of-care and sample sizes were small.
• Bottom line from the authors: evidence is still preliminary: "larger clinical trials are needed."

2. Vaccines - efficacy and safety concerns

• Pooled 14 studies (2020-2025): TAK-003 (Qdenga) and TV005 showed the highest protection.
• TAK-003 reduced risk of hospitalized/symptomatic dengue by 85% (RR 0.15, 95% CI 0.07-0.33) in its trial populations.
• Safety varied: TAK-003 and CYD-TDV (Dengvaxia) reduced serious events overall, while TV005 had more reactogenicity.

• Efficacy varies by serotype, serological status, and age.
• In moderate-to-high transmission settings, routine vaccination of children >6 years could cut hospitalized dengue burden by only 10-22% over 10 years - more modest than headline efficacy numbers suggest.
• Evidence of vaccine-induced disease enhancement risk in seronegative recipients for serotypes 3 and 4, especially in children under 6. This directly validates the caution I gave earlier: pre-vaccination serostatus matters, and benefit is uncertain in lower-transmission areas.

3. Prevention / vector control - mixed real-world results

4. Complications / problems - severity data

• 10.1% of ICU dengue admissions developed complications requiring non-invasive ventilation, invasive ventilation, vasopressors, blood transfusion, or renal replacement therapy (103 needed dialysis).
• Independent risk factors for complications: age ≥80 (OR 3.10), liver cirrhosis (OR 3.65), chronic kidney disease (OR 2.94), platelets <50,000/mm³ (OR 2.25), leukocytes >7,000/mm³ (OR 2.47).
• A machine-learning risk tool was proposed for early identification - useful context given Brazil accounted for 71% of global dengue cases in 2024.

Overall synthesis

• Drugs: still no approved antiviral; doxycycline+papaya extract and rupatadine are the most promising investigational options but not yet standard care; avoid NSAIDs/aspirin.
• Vaccines: TAK-003/Qdenga is the current best performer, but seronegative vaccinees (especially young children) carry a real enhancement risk for serotypes 3/4 - vaccination strategy should be transmission-setting- and serostatus-dependent.
• Prevention: conventional vector control has weaker trial evidence than assumed; Wolbachia-mosquito programs are the strongest emerging intervention.
• Complications: age, comorbidities (renal/hepatic disease), and lab markers (low platelets, high leukocytes) predict who is more likely to need ICU-level intervention - useful for triage in endemic settings.